ID   ABCR_HUMAN     STANDARD;      PRT;  2273 AA.
AC   P78363; O15112; O60438; O60915;
DT   30-MAY-2000 (Rel. 39, Created)
DT   30-MAY-2000 (Rel. 39, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Retinal-specific ATP-binding cassette transporter (ATP-binding
DE   cassette, sub-family A, member 4) (RIM ABC transporter) (RIM protein)
DE   (RmP) (Stargardt disease protein).
GN   Name=ABCA4; Synonyms=ABCR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A., VARIANTS STGD, AND VARIANTS HIS-846 AND GLN-943.
RX   MEDLINE=97207641; PubMed=9054934;
RA   Allikmets R., Singh N., Sun H., Shroyer N.F., Hutchinson A.,
RA   Chidambaram A., Gerrard B., Baird L., Stauffer D., Peiffer A.,
RA   Rattner A., Smallwood P.M., Li Y., Anderson K.L., Lewis R.A.,
RA   Nathans J., Leppert M., Dean M., Lupski J.R.;
RT   "A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is
RT   mutated in recessive Stargardt macular dystrophy.";
RL   Nat. Genet. 15:236-246(1997).
RN   [2]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=97345663; PubMed=9202155; DOI=10.1016/S0014-5793(97)00517-6;
RA   Azarian S.M., Travis G.H.;
RT   "The photoreceptor rim protein is an ABC transporter encoded by the
RT   gene for recessive Stargardt's disease (ABCR).";
RL   FEBS Lett. 409:247-252(1997).
RN   [3]
RP   SEQUENCE FROM N.A., AND VARIANTS STGD TRP-18 AND CYS-212.
RX   MEDLINE=98163759; PubMed=9503029; DOI=10.1006/geno.1997.5164;
RA   Gerber S., Rozet J.-M., van de Pol T.J.R., Hoyng C.B., Munnich A.,
RA   Blankenagel A., Kaplan J., Cremers F.P.M.;
RT   "Complete exon-intron structure of the retina-specific ATP binding
RT   transporter gene (ABCR) allows the identification of novel mutations
RT   underlying Stargardt disease.";
RL   Genomics 48:139-142(1998).
RN   [4]
RP   SEQUENCE FROM N.A., AND VARIANTS STGD.
RX   MEDLINE=98141123; PubMed=9490294;
RA   Nasonkin I., Illing M., Koehler M.R., Schmid M., Molday R.S.,
RA   Weber B.H.F.;
RT   "Mapping of the rod photoreceptor ABC transporter (ABCR) to 1p21-p22.1
RT   and identification of novel mutations in Stargardt's disease.";
RL   Hum. Genet. 102:21-26(1998).
RN   [5]
RP   CHARACTERIZATION.
RX   MEDLINE=99175213; PubMed=10075733; DOI=10.1074/jbc.274.12.8269;
RA   Sun H., Molday R.S., Nathans J.;
RT   "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR,
RT   the photoreceptor-specific ATP-binding cassette transporter
RT   responsible for Stargardt disease.";
RL   J. Biol. Chem. 274:8269-8281(1999).
RN   [6]
RP   DISEASE.
RX   MEDLINE=98133912; PubMed=9466990; DOI=10.1093/hmg/7.3.355;
RA   Cremers F.P.M., van de Pol D.J.R., van Driel M.A., den Hollander A.I.,
RA   van Haren F.J.J., Knoers N.V.A.M., Tijmes N., Bergen A.A.B.,
RA   Rohrschneider K., Blankenagel A., Pinckers A.J.L.G., Deutman A.F.,
RA   Hoyng C.B.;
RT   "Autosomal recessive retinitis pigmentosa and cone-rod dystrophy
RT   caused by splice site mutations in the Stargardt's disease gene
RT   ABCR.";
RL   Hum. Mol. Genet. 7:355-362(1998).
RN   [7]
RP   VARIANTS ARMD2, AND VARIANTS.
RX   MEDLINE=97442530; PubMed=9295268; DOI=10.1126/science.277.5333.1805;
RA   Allikmets R., Shroyer N.F., Singh N., Seddon J.M., Lewis R.A.,
RA   Bernstein P.S., Peiffer A., Zabriskie N.A., Li Y., Hutchinson A.,
RA   Dean M., Lupski J.R., Leppert M.;
RT   "Mutation of the Stargardt disease gene (ABCR) in age-related macular
RT   degeneration.";
RL   Science 277:1805-1807(1997).
RN   [8]
RP   VARIANTS STGD TRP-18; CYS-212; HIS-636; MET-1019; VAL-1038; CYS-1108;
RP   TRP-1640; SER-1977 AND HIS-2107, AND VARIANTS FFM PRO-11; PRO-541;
RP   VAL-1038; GLU-1091; CYS-1508; PHE-1970 AND ARG-1971.
RX   MEDLINE=98454319; PubMed=9781034; DOI=10.1038/sj.ejhg.5200221;
RA   Rozet J.-M., Gerber S., Souied E., Perrault I., Chatelin S., Ghazi I.,
RA   Leowski C., Dufier J.-L., Munnich A., Kaplan J.;
RT   "Spectrum of ABCR gene mutations in autosomal recessive macular
RT   dystrophies.";
RL   Eur. J. Hum. Genet. 6:291-295(1998).
RN   [9]
RP   VARIANTS STGD.
RX   MEDLINE=99138655; PubMed=9973280;
RA   Lewis R.A., Shroyer N.F., Singh N., Allikmets R., Hutchinson A.,
RA   Li Y., Lupski J.R., Leppert M., Dean M.;
RT   "Genotype/phenotype analysis of a photoreceptor-specific ATP-binding
RT   cassette transporter gene, ABCR, in Stargardt disease.";
RL   Am. J. Hum. Genet. 64:422-434(1999).
RN   [10]
RP   VARIANTS STGD, AND VARIANTS.
RX   MEDLINE=99192348; PubMed=10090887;
RA   Maugeri A., van Driel M.A., van de Pol D.J.R., Klevering B.J.,
RA   van Haren F.J.J., Tijmes N., Bergen A.A.B., Rohrschneider K.,
RA   Blankenagel A., Pinckers A.J.L.G., Dahl N., Brunner H.G.,
RA   Deutman A.F., Hoyng C.B., Cremers F.P.M.;
RT   "The 2588G-->C mutation in the ABCR gene is a mild frequent founder
RT   mutation in the western European population and allows the
RT   classification of ABCR Mutations in patients with Stargardt disease.";
RL   Am. J. Hum. Genet. 64:1024-1035(1999).
RN   [11]
RP   VARIANT STGD TYR-54, AND VARIANT ALA-863.
RX   MEDLINE=20077755; PubMed=10612508; DOI=10.1016/S0002-9394(99)00236-6;
RA   Zhang K., Garibaldi D.C., Kniazeva M., Albini T., Chiang M.F.,
RA   Kerrigan M., Sunness J.S., Han M., Allikmets R.;
RT   "A novel mutation in the ABCR gene in four patients with autosomal
RT   recessive Stargardt disease.";
RL   Am. J. Ophthalmol. 128:720-724(1999).
RN   [12]
RP   VARIANTS STGD VAL-60; ARG-206; ASN-300; PRO-541; ALA-849; PRO-974;
RP   VAL-1038; CYS-1108; LEU-1408; ARG-1488; ASP-1652; PRO-1729; GLU-1961;
RP   TRP-2038; TRP-2077; HIS-2107; ARG-2128 AND TYR-2150.
RX   MEDLINE=99221420; PubMed=10206579;
RA   Fishman G.A., Stone E.M., Grover S., Derlacki D.J., Haines H.L.,
RA   Hockey R.R.;
RT   "Variation of clinical expression in patients with Stargardt dystrophy
RT   and sequence variations in the ABCR gene.";
RL   Arch. Ophthalmol. 117:504-510(1999).
RN   [13]
RP   VARIANTS GLU-1961 AND ASN-2177.
RX   MEDLINE=20349288; PubMed=10880298;
RA   Allikmets R., Tammur J., Hutchinson A., Lewis R.A., Shroyer N.F.,
RA   Dalakishvili K., Lupski J.R., Steiner K., Pauleikhoff D., Holz F.G.,
RA   Weber B.H.F., Dean M., Atkinson A., Gail M.H., Bernstein P.S.,
RA   Singh N., Peiffer A., Zabriskie N.A., Leppert M., Seddon J.M.,
RA   Zhang K., Sunness J.S., Udar N.S., Yelchits S., Silva-Garcia R.,
RA   Small K.W., Simonelli F., Testa F., D'Urso M., Brancato R.,
RA   Rinaldi E., Ingvast S., Taube A., Wadelius C., Souied E., Ducroq D.,
RA   Kaplan J., Assink J.J.M., ten Brink J.B., de Jong P.T.V.M.,
RA   Bergen A.A.B., Maugeri A., van Driel M.A., Hoyng C.B., Cremers F.P.M.,
RA   Paloma E., Coco R., Balcells S., Gonzalez-Duarte R., Kermani S.,
RA   Stanga P., Bhattacharya S.S., Bird A.C.;
RT   "Further evidence for an association of ABCR alleles with age-related
RT   macular degeneration.";
RL   Am. J. Hum. Genet. 67:487-491(2000).
RN   [14]
RP   VARIANTS STGD GLU-60; THR-60; GLU-65; LEU-68; ARG-72; CYS-212;
RP   SER-230; SER-247; VAL-328; LYS-471; PRO-541; GLN-572; ARG-607;
RP   LYS-635; CYS-653; TYR-764; ARG-765; ALA-901; ILE-959; LYS-1036;
RP   VAL-1038; PRO-1063; ASP-1087; CYS-1097; CYS-1108; LEU-1380; LYS-1399;
RP   PRO-1430; VAL-1440; HIS-1443; LEU-1486; TYR-1488; MET-1537; PRO-1689;
RP   LEU-1705; THR-1733; ARG-1748; PRO-1763; LYS-1885; HIS-1898; GLU-1961;
RP   ARG-1975; SER-1977; GLY-2077; TRP-2077 AND VAL-2241, AND VARIANTS
RP   GLN-152; HIS-212; ARG-423; ILE-552; ARG-914; GLN-943; THR-1562;
RP   ILE-1868; MET-1921; LEU-1948; PHE-1970; ALA-2059; ASN-2177 AND
RP   VAL-2216.
RX   MEDLINE=20442027; PubMed=10958763;
RA   Rivera A., White K., Stoehr H., Steiner K., Hemmrich N., Grimm T.,
RA   Jurklies B., Lorenz B., Scholl H.P.N., Apfelstedt-Sylla E.,
RA   Weber B.H.F.;
RT   "A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene
RT   in Stargardt disease and age-related macular degeneration.";
RL   Am. J. Hum. Genet. 67:800-813(2000).
RN   [15]
RP   VARIANTS CORD3 GLU-65; CYS-212; PRO-541; ALA-863; GLY-863 DEL;
RP   VAL-1038; LYS-1122; TYR-1490 AND ASP-1598.
RX   MEDLINE=20442040; PubMed=10958761;
RA   Maugeri A., Klevering B.J., Rohrschneider K., Blankenagel A.,
RA   Brunner H.G., Deutman A.F., Hoyng C.B., Cremers F.P.M.;
RT   "Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal
RT   recessive cone-rod dystrophy.";
RL   Am. J. Hum. Genet. 67:960-966(2000).
RN   [16]
RP   VARIANTS STGD ASP-340; GLN-572; ALA-863; SER-965; VAL-1038; ALA-1780
RP   AND HIS-1898, AND VARIANT GLN-943.
RX   MEDLINE=20208356; PubMed=10746567;
RA   Shroyer N.F., Lewis R.A., Lupski J.R.;
RT   "Complex inheritance of ABCR mutations in Stargardt disease: linkage
RT   disequilibrium, complex alleles, and pseudodominance.";
RL   Hum. Genet. 106:244-248(2000).
RN   [17]
RP   VARIANTS STGD.
RX   MEDLINE=20098082; PubMed=10634594;
RA   Papaioannou M., Ocaka L., Bessant D., Lois N., Bird A.C., Payne A.,
RA   Bhattacharya S.S.;
RT   "An analysis of ABCR mutations in British patients with recessive
RT   retinal dystrophies.";
RL   Invest. Ophthalmol. Vis. Sci. 41:16-19(2000).
RN   [18]
RP   VARIANTS STGD CYS-212; ASP-767; ILE-897; VAL-1038; LYS-1087; LYS-1399;
RP   GLN-1640 AND GLU-1961, AND VARIANT HIS-212.
RX   MEDLINE=20174852; PubMed=10711710;
RA   Simonelli F., Testa F., de Crecchio G., Rinaldi E., Hutchinson A.,
RA   Atkinson A., Dean M., D'Urso M., Allikmets R.;
RT   "New ABCR mutations and clinical phenotype in Italian patients with
RT   Stargardt disease.";
RL   Invest. Ophthalmol. Vis. Sci. 41:892-897(2000).
RN   [19]
RP   CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLY-966; LYS-969;
RP   GLY-1975 AND LYS-1978.
RX   MEDLINE=20472331; PubMed=11017087; DOI=10.1038/79994;
RA   Sun H., Smallwood P.M., Nathans J.;
RT   "Biochemical defects in ABCR protein variants associated with human
RT   retinopathies.";
RL   Nat. Genet. 26:242-246(2000).
RN   [20]
RP   VARIANT STGD ASN-972, AND VARIANTS GLN-943; ILE-1868 AND LEU-1948.
RX   MEDLINE=21478761; PubMed=11594993;
RA   Eksandh L., Ekstroem U., Abrahamson M., Bauer B., Andreasson S.;
RT   "Different clinical expressions in two families with Stargardt's
RT   macular dystrophy (STGD1).";
RL   Acta Ophthalmol. Scand. 79:524-530(2001).
RN   [21]
RP   VARIANTS RETINAL TOXICITY CYS-1129; ARG-1201 AND HIS-2107, AND
RP   VARIANTS HIS-212; ARG-423; ILE-1868 AND ILE-2255.
RX   MEDLINE=21278097; PubMed=11384574; DOI=10.1016/S0002-9394(01)00838-8;
RA   Shroyer N.F., Lewis R.A., Lupski J.R.;
RT   "Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is
RT   retinal toxicity by chloroquine and hydroxychloroquine related to
RT   Stargardt disease?";
RL   Am. J. Ophthalmol. 131:761-766(2001).
RN   [22]
RP   VARIANTS GLU-1961 AND ASN-2177.
RX   MEDLINE=21244305; PubMed=11346402;
RA   Guymer R.H., Heon E., Lotery A.J., Munier F.L., Schorderet D.F.,
RA   Baird P.N., McNeil R.J., Haines H.L., Sheffield V.C., Stone E.M.;
RT   "Variation of codons 1961 and 2177 of the Stargardt disease gene is
RT   not associated with age-related macular degeneration.";
RL   Arch. Ophthalmol. 119:745-751(2001).
RN   [23]
RP   VARIANTS FFM GLY-339; ALA-863; TRP-943; ARG-991; VAL-1038; CYS-1108;
RP   ARG-1488; THR-1562; GLN-1640; PHE-2027; GLN-2030 AND CYS-2106, AND
RP   VARIANTS HIS-212; ARG-423; GLN-943; THR-1148; ILE-1868 AND ILE-2255.
RX   MEDLINE=21270950; PubMed=11379881;
RA   Yatsenko A.N., Shroyer N.F., Lewis R.A., Lupski J.R.;
RT   "Late-onset Stargardt disease is associated with missense mutations
RT   that map outside known functional regions of ABCR (ABCA4).";
RL   Hum. Genet. 108:346-355(2001).
RN   [24]
RP   VARIANTS STGD SER-686; TRP-1055; ASP-1799; ASP-1805; PRO-1940 AND
RP   HIS-2107, VARIANTS FFM MET-1253 AND PRO-1940, VARIANTS CORD3 CYS-212
RP   AND ARG-2060, AND VARIANTS GLN-943; LEU-1948 AND ILE-2255.
RX   MEDLINE=21278628; PubMed=11385708; DOI=10.1002/humu.1133;
RA   Paloma E., Martinez-Mir A., Vilageliu L., Gonzalez-Duarte R.,
RA   Balcells S.;
RT   "Spectrum of ABCA4 (ABCR) gene mutations in Spanish patients with
RT   autosomal recessive macular dystrophies.";
RL   Hum. Mutat. 17:504-510(2001).
RN   [25]
RP   VARIANTS STGD, AND VARIANTS.
RX   MEDLINE=21226556; PubMed=11328725;
RA   Webster A.R., Heon E., Lotery A.J., Vandenburgh K., Casavant T.L.,
RA   Oh K.T., Beck G., Fishman G.A., Lam B.L., Levin A., Heckenlively J.R.,
RA   Jacobson S.G., Weleber R.G., Sheffield V.C., Stone E.M.;
RT   "An analysis of allelic variation in the ABCA4 gene.";
RL   Invest. Ophthalmol. Vis. Sci. 42:1179-1189(2001).
RN   [26]
RP   VARIANTS STGD 13-LYS--TRP-15 DEL; TYR-54; LYS-58; VAL-60; GLU-65;
RP   GLU-77; HIS-190; PRO-244; ARG-309; CYS-525; CYS-537; PRO-541; PRO-549;
RP   ARG-550; GLN-602; ARG-607; MET-643; ASP-767; PRO-797; ARG-821;
RP   THR-824; ALA-863; ALA-935; TRP-943; ALA-989; VAL-1038; CYS-1108;
RP   LEU-1108; LYS-1122; ARG-1201; GLN-1300; LEU-1380; PRO-1388; ARG-1408;
RP   LEU-1486; ARG-1488; TYR-1490; MET-1526; ASN-1532; THR-1562; TRP-1640;
RP   LEU-1776; THR-1846; GLU-1961; SER-1977; PHE-2027; GLN-2030; PRO-2035;
RP   LEU-2050; CYS-2107; HIS-2107; TRP-2139; ARG-2150 AND TYR-2150,
RP   VARIANTS CORD3 GLN-1640 AND ASP-2146, AND VARIANTS HIS-212; ARG-423;
RP   GLN-943; THR-1637; ILE-1868 AND LEU-1948.
RX   MEDLINE=21419317; PubMed=11527935;
RA   Briggs C.E., Rucinski D., Rosenfeld P.J., Hirose T., Berson E.L.,
RA   Dryja T.P.;
RT   "Mutations in ABCR (ABCA4) in patients with Stargardt macular
RT   degeneration or cone-rod degeneration.";
RL   Invest. Ophthalmol. Vis. Sci. 42:2229-2236(2001).
CC   -!- FUNCTION: May play a role in photoresponse. Retinoids, and most
CC       likely retinal, are the natural substrates for transport by abcr
CC       in rod outer segments. May act in the visual cycle to flip PE-all-
CC       trans-retinal adducts from the lumenal to the cytosolic face of
CC       the disk membrane, move free all-trans-retinal from the lipid
CC       phase of the disk membrane to a juxtamembrane location, or
CC       possibly reorient all-trans-retinal in the bilayer.
CC   -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC   -!- TISSUE SPECIFICITY: Retinal-specific. Seems to be exclusively
CC       found in the rims of rod photoreceptor cells.
CC   -!- POLYMORPHISM: The variant Ala-863 is present in the general
CC       population at a frequency of approximately 3% and 1% in Northern
CC       Europe and United States, respectively. It is a mild alteration
CC       probably leading to STGD phenotype only in combination with a more
CC       severe allele. The variant Glu-1961 is found with high frequency
CC       in healthy individuals of Somali ancestry.
CC   -!- DISEASE: Defects in ABCA4 are a cause of Stargardt disease (STGD)
CC       [MIM:248200]; also known as juvenile macular degeneration. STGD is
CC       an autosomal recessive retinal disorder and one of the most
CC       frequent causes of macular degeneration in childhood. It is
CC       characterized by macular dystrophy with juvenile-onset, rapidly
CC       progressive course, alterations of the peripheral retina, and
CC       subretinal deposition of lipofuscin-like material.
CC   -!- DISEASE: Defects in ABCA4 are the cause of fundus flavimaculatus
CC       (FFM) [MIM:248200]. FFM is an autosomal recessive retinal disorder
CC       very similar to Stargardt disease. In contrast to Stargardt
CC       disease, FFM is characterized by later onset and slowly
CC       progressive course.
CC   -!- DISEASE: Defects in ABCA4 may be a cause of age-related macular
CC       degeneration 2 (ARMD2) [MIM:153800].
CC   -!- DISEASE: Defects in ABCA4 are the cause of cone-rod dystrophy 3
CC       (CORD3) [MIM:604116]. Inheritance is autosomal recessive.
CC   -!- DISEASE: Defects in ABCA4 are the cause of retinitis pigmentosa 19
CC       (RP19) [MIM:601718]. RP19 is characterized by choroidal atrophy.
CC       Inheritance is autosomal recessive.
CC   -!- SIMILARITY: Belongs to the ABC transporter family. ABCA subfamily.
CC   -!- DATABASE: NAME=Mutations of the ABCA4 gene;
CC       NOTE=Retina International's Scientific Newsletter;
CC       WWW="http://www.retina-international.com/sci-news/abcrmut.htm".
CC   --------------------------------------------------------------------------
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use  by  non-profit  institutions as long  as its content  is  in  no  way
CC   modified and this statement is not removed.  Usage  by  and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC   or send an email to license@isb-sib.ch).
CC   --------------------------------------------------------------------------
DR   EMBL; U88667; AAC51144.1; -.
DR   EMBL; AF000148; AAC23915.1; -.
DR   EMBL; Y15635; CAA75729.1; -.
DR   EMBL; Y15636; CAA75729.1; JOINED.
DR   EMBL; Y15637; CAA75729.1; JOINED.
DR   EMBL; Y15638; CAA75729.1; JOINED.
DR   EMBL; Y15639; CAA75729.1; JOINED.
DR   EMBL; Y15640; CAA75729.1; JOINED.
DR   EMBL; Y15641; CAA75729.1; JOINED.
DR   EMBL; Y15642; CAA75729.1; JOINED.
DR   EMBL; Y15643; CAA75729.1; JOINED.
DR   EMBL; Y15644; CAA75729.1; JOINED.
DR   EMBL; Y15645; CAA75729.1; JOINED.
DR   EMBL; Y15646; CAA75729.1; JOINED.
DR   EMBL; Y15647; CAA75729.1; JOINED.
DR   EMBL; Y15648; CAA75729.1; JOINED.
DR   EMBL; Y15649; CAA75729.1; JOINED.
DR   EMBL; Y15650; CAA75729.1; JOINED.
DR   EMBL; Y15651; CAA75729.1; JOINED.
DR   EMBL; Y15652; CAA75729.1; JOINED.
DR   EMBL; Y15653; CAA75729.1; JOINED.
DR   EMBL; Y15654; CAA75729.1; JOINED.
DR   EMBL; Y15655; CAA75729.1; JOINED.
DR   EMBL; Y15656; CAA75729.1; JOINED.
DR   EMBL; Y15657; CAA75729.1; JOINED.
DR   EMBL; Y15658; CAA75729.1; JOINED.
DR   EMBL; Y15659; CAA75729.1; JOINED.
DR   EMBL; Y15660; CAA75729.1; JOINED.
DR   EMBL; Y15661; CAA75729.1; JOINED.
DR   EMBL; Y15662; CAA75729.1; JOINED.
DR   EMBL; Y15663; CAA75729.1; JOINED.
DR   EMBL; Y15664; CAA75729.1; JOINED.
DR   EMBL; Y15665; CAA75729.1; JOINED.
DR   EMBL; Y15666; CAA75729.1; JOINED.
DR   EMBL; Y15667; CAA75729.1; JOINED.
DR   EMBL; Y15668; CAA75729.1; JOINED.
DR   EMBL; Y15669; CAA75729.1; JOINED.
DR   EMBL; Y15670; CAA75729.1; JOINED.
DR   EMBL; Y15671; CAA75729.1; JOINED.
DR   EMBL; Y15672; CAA75729.1; JOINED.
DR   EMBL; Y15673; CAA75729.1; JOINED.
DR   EMBL; Y15674; CAA75729.1; JOINED.
DR   EMBL; Y15675; CAA75729.1; JOINED.
DR   EMBL; Y15676; CAA75729.1; JOINED.
DR   EMBL; Y15677; CAA75729.1; JOINED.
DR   EMBL; Y15678; CAA75729.1; JOINED.
DR   EMBL; Y15679; CAA75729.1; JOINED.
DR   EMBL; Y15680; CAA75729.1; JOINED.
DR   EMBL; Y15681; CAA75729.1; JOINED.
DR   EMBL; Y15682; CAA75729.1; JOINED.
DR   EMBL; Y15683; CAA75729.1; JOINED.
DR   EMBL; Y15684; CAA75729.1; JOINED.
DR   EMBL; AF001945; AAC05632.1; -.
DR   Genew; HGNC:34; ABCA4.
DR   MIM; 601691; -.
DR   MIM; 153800; -.
DR   MIM; 248200; -.
DR   MIM; 601718; -.
DR   MIM; 604116; -.
DR   GO; GO:0005624; C:membrane fraction; TAS.
DR   GO; GO:0004009; F:ATP-binding cassette (ABC) transporter acti...; TAS.
DR   GO; GO:0005215; F:transporter activity; TAS.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS.
DR   GO; GO:0006810; P:transport; TAS.
DR   GO; GO:0007601; P:visual perception; TAS.
DR   InterPro; IPR003439; ABC_transporter.
DR   InterPro; IPR005951; Rim_ABC_transpt.
DR   Pfam; PF00005; ABC_tran; 2.
DR   ProDom; PD000006; ABC_transporter; 2.
DR   TIGRFAMs; TIGR01257; rim_protein; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
KW   ATP-binding; Cone-rod dystrophy; Disease mutation; Glycoprotein;
KW   Polymorphism; Repeat; Retinitis pigmentosa; Stargardt disease;
KW   Transmembrane; Transport; Vision.
FT   TRANSMEM    547    567       Potential.
FT   TRANSMEM    647    667       Potential.
FT   TRANSMEM    700    720       Potential.
FT   TRANSMEM    731    751       Potential.
FT   TRANSMEM    760    780       Potential.
FT   TRANSMEM    836    856       Potential.
FT   TRANSMEM   1072   1092       Potential.
FT   TRANSMEM   1377   1397       Potential.
FT   TRANSMEM   1560   1580       Potential.
FT   TRANSMEM   1682   1702       Potential.
FT   TRANSMEM   1729   1749       Potential.
FT   TRANSMEM   1760   1780       Potential.
FT   TRANSMEM   1793   1813       Potential.
FT   TRANSMEM   1875   1895       Potential.
FT   DOMAIN      929   1160       ABC transporter 1.
FT   DOMAIN     1938   2170       ABC transporter 2.
FT   NP_BIND     963    970       ATP (Potential).
FT   NP_BIND    1972   1979       ATP (Potential).
FT   CARBOHYD     14     14       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     98     98       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    415    415       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    444    444       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    504    504       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    950    950       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1469   1469       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1529   1529       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1588   1588       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1662   1662       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1707   1707       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1819   1819       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1933   1933       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2006   2006       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2052   2052       N-linked (GlcNAc...) (Potential).
FT   VARIANT      11     11       L -> P (in FFM).
FT                                /FTId=VAR_012493.
FT   VARIANT      13     15       Missing (in STGD).
FT                                /FTId=VAR_012494.
FT   VARIANT      18     18       R -> W (in STGD).
FT                                /FTId=VAR_008398.
FT   VARIANT      24     24       R -> H (in STGD).
FT                                /FTId=VAR_008399.
FT   VARIANT      54     54       C -> Y (in STGD).
FT                                /FTId=VAR_008400.
FT   VARIANT      58     58       N -> K (in STGD).
FT                                /FTId=VAR_012495.
FT   VARIANT      60     60       A -> E (in STGD).
FT                                /FTId=VAR_012496.
FT   VARIANT      60     60       A -> T (in STGD).
FT                                /FTId=VAR_012497.
FT   VARIANT      60     60       A -> V (in STGD).
FT                                /FTId=VAR_008492.
FT   VARIANT      65     65       G -> E (in STGD and CORD3).
FT                                /FTId=VAR_008401.
FT   VARIANT      68     68       P -> L (in STGD).
FT                                /FTId=VAR_012498.
FT   VARIANT      68     68       P -> R (in STGD).
FT                                /FTId=VAR_012499.
FT   VARIANT      72     72       G -> R (in STGD).
FT                                /FTId=VAR_012500.
FT   VARIANT      75     75       C -> G (in STGD).
FT                                /FTId=VAR_008402.
FT   VARIANT      77     77       V -> E (in STGD).
FT                                /FTId=VAR_012501.
FT   VARIANT      96     96       N -> D (in STGD).
FT                                /FTId=VAR_008403.
FT   VARIANT      96     96       N -> H (in STGD).
FT                                /FTId=VAR_008404.
FT   VARIANT     100    100       S -> P (in STGD).
FT                                /FTId=VAR_012502.
FT   VARIANT     152    152       R -> Q.
FT                                /FTId=VAR_012503.
FT   VARIANT     156    156       I -> V (in STGD).
FT                                /FTId=VAR_012504.
FT   VARIANT     190    190       Q -> H (in STGD).
FT                                /FTId=VAR_012505.
FT   VARIANT     192    192       A -> T (in STGD).
FT                                /FTId=VAR_008405.
FT   VARIANT     206    206       S -> R (in STGD; reduced basal and
FT                                retinal-stimulated ATP-hydrolysis).
FT                                /FTId=VAR_012506.
FT   VARIANT     212    212       R -> C (in STGD and CORD3; common
FT                                mutation in southern Europe; reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008406.
FT   VARIANT     212    212       R -> H.
FT                                /FTId=VAR_012507.
FT   VARIANT     220    220       R -> C (in STGD).
FT                                /FTId=VAR_012508.
FT   VARIANT     230    230       C -> S (in STGD).
FT                                /FTId=VAR_012509.
FT   VARIANT     244    244       L -> P (in STGD).
FT                                /FTId=VAR_012510.
FT   VARIANT     247    247       N -> S (in STGD).
FT                                /FTId=VAR_012511.
FT   VARIANT     249    249       D -> G (in STGD).
FT                                /FTId=VAR_008407.
FT   VARIANT     300    300       T -> N (in STGD).
FT                                /FTId=VAR_008408.
FT   VARIANT     309    309       P -> R (in STGD).
FT                                /FTId=VAR_012512.
FT   VARIANT     328    328       E -> V (in STGD).
FT                                /FTId=VAR_012513.
FT   VARIANT     333    333       R -> W (in STGD).
FT                                /FTId=VAR_012514.
FT   VARIANT     336    336       S -> C (in STGD).
FT                                /FTId=VAR_008409.
FT   VARIANT     339    339       W -> G (in FFM).
FT                                /FTId=VAR_012515.
FT   VARIANT     340    340       Y -> D (in STGD).
FT                                /FTId=VAR_008410.
FT   VARIANT     380    380       N -> K (in STGD).
FT                                /FTId=VAR_012516.
FT   VARIANT     407    407       A -> V (in STGD and CORD3).
FT                                /FTId=VAR_008411.
FT   VARIANT     423    423       H -> R.
FT                                /FTId=VAR_012517.
FT   VARIANT     445    445       S -> R (in STGD).
FT                                /FTId=VAR_008412.
FT   VARIANT     471    471       E -> K (in ARMD2 and STGD; ATP-binding
FT                                capacity and retinal stimulation as in
FT                                wild type; dbSNP:1800548).
FT                                /FTId=VAR_008413.
FT   VARIANT     523    523       D -> E (in STGD).
FT                                /FTId=VAR_008414.
FT   VARIANT     525    525       F -> C (in STGD).
FT                                /FTId=VAR_012518.
FT   VARIANT     537    537       R -> C (in STGD).
FT                                /FTId=VAR_012519.
FT   VARIANT     541    541       L -> P (in STGD, FFM and CORD3; reduced
FT                                ATP-binding capacity; abolishes retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008415.
FT   VARIANT     549    549       A -> P (in STGD).
FT                                /FTId=VAR_012520.
FT   VARIANT     550    550       G -> R (in STGD).
FT                                /FTId=VAR_012521.
FT   VARIANT     552    552       V -> I.
FT                                /FTId=VAR_012522.
FT   VARIANT     572    572       R -> P (in STGD).
FT                                /FTId=VAR_008416.
FT   VARIANT     572    572       R -> Q (in STGD).
FT                                /FTId=VAR_008417.
FT   VARIANT     602    602       R -> W (in STGD).
FT                                /FTId=VAR_008418.
FT   VARIANT     602    602       R -> Q (in STGD).
FT                                /FTId=VAR_012523.
FT   VARIANT     607    607       G -> R (in STGD).
FT                                /FTId=VAR_012524.
FT   VARIANT     607    607       G -> W (in STGD).
FT                                /FTId=VAR_012525.
FT   VARIANT     608    608       F -> I (in STGD).
FT                                /FTId=VAR_008419.
FT   VARIANT     635    635       Q -> K (in STGD).
FT                                /FTId=VAR_012526.
FT   VARIANT     636    636       Q -> H (in STGD).
FT                                /FTId=VAR_012527.
FT   VARIANT     643    643       V -> G.
FT                                /FTId=VAR_008420.
FT   VARIANT     643    643       V -> M (in STGD).
FT                                /FTId=VAR_012528.
FT   VARIANT     645    645       D -> N (in STGD).
FT                                /FTId=VAR_008421.
FT   VARIANT     653    653       R -> C (in STGD).
FT                                /FTId=VAR_012529.
FT   VARIANT     686    686       L -> S (in STGD).
FT                                /FTId=VAR_012530.
FT   VARIANT     716    716       T -> M (in STGD).
FT                                /FTId=VAR_012531.
FT   VARIANT     752    752       S -> I (in dbSNP:1801369).
FT                                /FTId=VAR_014703.
FT   VARIANT     764    764       C -> Y (in STGD).
FT                                /FTId=VAR_012532.
FT   VARIANT     765    765       S -> R (in STGD).
FT                                /FTId=VAR_012533.
FT   VARIANT     765    765       S -> N (in STGD).
FT                                /FTId=VAR_012534.
FT   VARIANT     767    767       V -> D (in STGD).
FT                                /FTId=VAR_012535.
FT   VARIANT     797    797       L -> P (in STGD).
FT                                /FTId=VAR_012536.
FT   VARIANT     818    818       G -> E (in ARMD2 and STGD; reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008422.
FT   VARIANT     821    821       W -> R (in STGD).
FT                                /FTId=VAR_008423.
FT   VARIANT     824    824       I -> T (in STGD).
FT                                /FTId=VAR_012537.
FT   VARIANT     846    846       D -> H.
FT                                /FTId=VAR_008493.
FT   VARIANT     849    849       V -> A (in STGD).
FT                                /FTId=VAR_012538.
FT   VARIANT     851    851       G -> D (in STGD; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008424.
FT   VARIANT     854    854       A -> T (in STGD).
FT                                /FTId=VAR_012539.
FT   VARIANT     863    863       Missing (in STGD and CORD3; reduced ATP-
FT                                binding capacity and retinal-stimulated
FT                                ATP hydrolysis).
FT                                /FTId=VAR_012540.
FT   VARIANT     863    863       G -> A (in STGD, FFM and CORD3; frequent
FT                                mutation in northern Europe in linkage
FT                                disequilibrium with the polymorphic
FT                                variant Q-943; reduced ATP-binding
FT                                capacity and retinal-stimulated ATP
FT                                hydrolysis).
FT                                /FTId=VAR_008425.
FT   VARIANT     873    873       F -> L (in STGD).
FT                                /FTId=VAR_012541.
FT   VARIANT     897    897       T -> I (in STGD).
FT                                /FTId=VAR_012542.
FT   VARIANT     901    901       T -> A.
FT                                /FTId=VAR_008426.
FT   VARIANT     914    914       H -> R.
FT                                /FTId=VAR_012543.
FT   VARIANT     931    931       V -> M (in STGD).
FT                                /FTId=VAR_008427.
FT   VARIANT     935    935       V -> A (in STGD).
FT                                /FTId=VAR_012544.
FT   VARIANT     943    943       R -> Q (in linkage disequilibrium with A-
FT                                863 in the European population;
FT                                dbSNP:1801581).
FT                                /FTId=VAR_008428.
FT   VARIANT     943    943       R -> W (in STGD and FFM).
FT                                /FTId=VAR_012545.
FT   VARIANT     957    957       Q -> R (in STGD).
FT                                /FTId=VAR_008429.
FT   VARIANT     959    959       T -> I (in STGD).
FT                                /FTId=VAR_012546.
FT   VARIANT     965    965       N -> S (in STGD; reduced retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008430.
FT   VARIANT     971    971       T -> N (in STGD; highly reduced ATP-
FT                                binding capacity; abolishes retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_012547.
FT   VARIANT     972    972       T -> N (in STGD; could be a rare
FT                                polymorphism).
FT                                /FTId=VAR_012548.
FT   VARIANT     974    974       S -> P (in STGD).
FT                                /FTId=VAR_012549.
FT   VARIANT     978    978       G -> C (in STGD).
FT                                /FTId=VAR_008431.
FT   VARIANT     989    989       V -> A (in STGD).
FT                                /FTId=VAR_012550.
FT   VARIANT     991    991       G -> R (in FFM).
FT                                /FTId=VAR_012551.
FT   VARIANT    1014   1014       L -> R (in STGD).
FT                                /FTId=VAR_012552.
FT   VARIANT    1019   1019       T -> A (in STGD).
FT                                /FTId=VAR_012553.
FT   VARIANT    1019   1019       T -> M (in STGD).
FT                                /FTId=VAR_012554.
FT   VARIANT    1022   1022       E -> K (in STGD).
FT                                /FTId=VAR_012555.
FT   VARIANT    1031   1031       K -> E (in STGD).
FT                                /FTId=VAR_012556.
FT   VARIANT    1036   1036       E -> K (in STGD).
FT                                /FTId=VAR_008432.
FT   VARIANT    1038   1038       A -> V (in STGD, FFM and CORD3; frequent
FT                                mutation; reduced ATP-binding and
FT                                retinal-stimulated ATP hydrolysis).
FT                                /FTId=VAR_008433.
FT   VARIANT    1055   1055       R -> W (in STGD).
FT                                /FTId=VAR_012557.
FT   VARIANT    1063   1063       S -> P (in STGD).
FT                                /FTId=VAR_012558.
FT   VARIANT    1071   1071       S -> L (in STGD; reduced ATP-binding
FT                                capacity).
FT                                /FTId=VAR_008434.
FT   VARIANT    1072   1072       V -> A (in STGD).
FT                                /FTId=VAR_008435.
FT   VARIANT    1087   1087       E -> D (in STGD).
FT                                /FTId=VAR_012559.
FT   VARIANT    1087   1087       E -> K (in STGD).
FT                                /FTId=VAR_008436.
FT   VARIANT    1091   1091       G -> E (in FFM).
FT                                /FTId=VAR_012560.
FT   VARIANT    1097   1097       R -> C (in STGD).
FT                                /FTId=VAR_012561.
FT   VARIANT    1108   1108       R -> C (in STGD and FFM; reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_012562.
FT   VARIANT    1108   1108       R -> H (in STGD).
FT                                /FTId=VAR_012563.
FT   VARIANT    1108   1108       R -> L (in STGD).
FT                                /FTId=VAR_012564.
FT   VARIANT    1112   1112       T -> N (in STGD).
FT                                /FTId=VAR_008437.
FT   VARIANT    1122   1122       E -> K (in STGD and CORD3).
FT                                /FTId=VAR_008438.
FT   VARIANT    1129   1129       R -> C (in STGD; may predispose to
FT                                develop retinal toxicity after treatment
FT                                with chloroquine and hydroxychloroquine).
FT                                /FTId=VAR_012565.
FT   VARIANT    1129   1129       R -> L (in ARMD2, STGD and FFM; reduced
FT                                ATP-binding capacity; dbSNP:1801269).
FT                                /FTId=VAR_008439.
FT   VARIANT    1148   1148       K -> T.
FT                                /FTId=VAR_012566.
FT   VARIANT    1201   1201       L -> R (in STGD; may predispose to
FT                                develop retinal toxicity after treatment
FT                                with chloroquine and hydroxychloroquine).
FT                                /FTId=VAR_008440.
FT   VARIANT    1204   1204       D -> N (in STGD).
FT                                /FTId=VAR_008441.
FT   VARIANT    1250   1250       L -> P (in STGD).
FT                                /FTId=VAR_012567.
FT   VARIANT    1253   1253       T -> M (in FFM; could be a rare
FT                                polymorphism).
FT                                /FTId=VAR_012568.
FT   VARIANT    1300   1300       R -> Q (in STGD).
FT                                /FTId=VAR_012569.
FT   VARIANT    1314   1314       P -> T.
FT                                /FTId=VAR_008442.
FT   VARIANT    1380   1380       P -> L (in STGD; reduced ATP-binding
FT                                capacity).
FT                                /FTId=VAR_008443.
FT   VARIANT    1388   1388       L -> P (in STGD).
FT                                /FTId=VAR_012570.
FT   VARIANT    1399   1399       E -> K (in STGD).
FT                                /FTId=VAR_012571.
FT   VARIANT    1406   1406       H -> Y (in STGD).
FT                                /FTId=VAR_008444.
FT   VARIANT    1408   1408       W -> L (in STGD).
FT                                /FTId=VAR_008445.
FT   VARIANT    1408   1408       W -> R (in STGD; reduced retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008446.
FT   VARIANT    1428   1428       T -> M (in ARMD2; dbSNP:1800549).
FT                                /FTId=VAR_008447.
FT   VARIANT    1429   1429       V -> A (in STGD).
FT                                /FTId=VAR_008448.
FT   VARIANT    1430   1430       L -> P (in STGD).
FT                                /FTId=VAR_012572.
FT   VARIANT    1433   1433       V -> I (in STGD).
FT                                /FTId=VAR_008449.
FT   VARIANT    1439   1439       G -> D (in STGD).
FT                                /FTId=VAR_008450.
FT   VARIANT    1440   1440       F -> S (in STGD).
FT                                /FTId=VAR_008451.
FT   VARIANT    1440   1440       F -> V (in STGD).
FT                                /FTId=VAR_012573.
FT   VARIANT    1443   1443       R -> H (in STGD).
FT                                /FTId=VAR_012574.
FT   VARIANT    1486   1486       P -> L (in STGD).
FT                                /FTId=VAR_008452.
FT   VARIANT    1488   1488       C -> F (in STGD).
FT                                /FTId=VAR_012575.
FT   VARIANT    1488   1488       C -> R (in STGD and FFM; reduced retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008453.
FT   VARIANT    1488   1488       C -> Y (in STGD).
FT                                /FTId=VAR_012576.
FT   VARIANT    1490   1490       C -> Y (in STGD and CORD3; reduced
FT                                retinal-stimulated ATP hydrolysis).
FT                                /FTId=VAR_008454.
FT   VARIANT    1508   1508       G -> C (in FFM).
FT                                /FTId=VAR_012577.
FT   VARIANT    1513   1513       Q -> R (in STGD).
FT                                /FTId=VAR_012578.
FT   VARIANT    1517   1517       R -> S (in ARMD2; dbSNP:1800550).
FT                                /FTId=VAR_008455.
FT   VARIANT    1525   1525       L -> P (in STGD).
FT                                /FTId=VAR_012579.
FT   VARIANT    1526   1526       T -> M (in STGD; reduced retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008456.
FT   VARIANT    1532   1532       D -> N (in STGD).
FT                                /FTId=VAR_008457.
FT   VARIANT    1537   1537       T -> M (in STGD).
FT                                /FTId=VAR_012580.
FT   VARIANT    1562   1562       I -> T (in STGD, FFM, ARMD2 and CORD3;
FT                                dbSNP:1762111).
FT                                /FTId=VAR_008458.
FT   VARIANT    1578   1578       G -> R (in ARMD2; dbSNP:1800551).
FT                                /FTId=VAR_008459.
FT   VARIANT    1598   1598       A -> D (in CORD3).
FT                                /FTId=VAR_012581.
FT   VARIANT    1631   1631       L -> P (in STGD).
FT                                /FTId=VAR_008460.
FT   VARIANT    1637   1637       A -> T (rare polymorphism).
FT                                /FTId=VAR_012582.
FT   VARIANT    1640   1640       R -> Q (in STGD, FFM and CORD3).
FT                                /FTId=VAR_012583.
FT   VARIANT    1640   1640       R -> W (in STGD and CORD3).
FT                                /FTId=VAR_008461.
FT   VARIANT    1652   1652       Y -> D (in STGD).
FT                                /FTId=VAR_008462.
FT   VARIANT    1681   1685       Missing (in STGD; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_012584.
FT   VARIANT    1689   1689       S -> P (in STGD).
FT                                /FTId=VAR_012585.
FT   VARIANT    1693   1693       V -> I (in STGD).
FT                                /FTId=VAR_012586.
FT   VARIANT    1696   1696       S -> N (in STGD).
FT                                /FTId=VAR_008463.
FT   VARIANT    1703   1703       Q -> K (in STGD).
FT                                /FTId=VAR_008464.
FT   VARIANT    1705   1705       R -> L (in STGD).
FT                                /FTId=VAR_012587.
FT   VARIANT    1729   1729       L -> P (in STGD).
FT                                /FTId=VAR_008465.
FT   VARIANT    1733   1733       M -> T (in STGD).
FT                                /FTId=VAR_012588.
FT   VARIANT    1736   1736       S -> P (in STGD).
FT                                /FTId=VAR_012589.
FT   VARIANT    1748   1748       G -> R (in STGD).
FT                                /FTId=VAR_012590.
FT   VARIANT    1761   1763       Missing (in STGD; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_012591.
FT   VARIANT    1763   1763       L -> P (in STGD).
FT                                /FTId=VAR_012592.
FT   VARIANT    1776   1776       P -> L (in STGD).
FT                                /FTId=VAR_012593.
FT   VARIANT    1780   1780       P -> A (in STGD).
FT                                /FTId=VAR_012594.
FT   VARIANT    1794   1794       A -> D (in STGD).
FT                                /FTId=VAR_008466.
FT   VARIANT    1799   1799       N -> D (in STGD).
FT                                /FTId=VAR_012595.
FT   VARIANT    1805   1805       N -> D (in STGD).
FT                                /FTId=VAR_012596.
FT   VARIANT    1817   1817       E -> D.
FT                                /FTId=VAR_012597.
FT   VARIANT    1820   1820       R -> P (in STGD).
FT                                /FTId=VAR_008467.
FT   VARIANT    1838   1838       H -> Y (in STGD).
FT                                /FTId=VAR_008468.
FT   VARIANT    1843   1843       R -> W (in STGD).
FT                                /FTId=VAR_008469.
FT   VARIANT    1846   1846       I -> T.
FT                                /FTId=VAR_008494.
FT   VARIANT    1868   1868       N -> I (slightly reduced retinal-
FT                                stimulated ATP hydrolysis;
FT                                dbSNP:1801466).
FT                                /FTId=VAR_008470.
FT   VARIANT    1884   1884       V -> E (in STGD).
FT                                /FTId=VAR_012598.
FT   VARIANT    1885   1885       E -> K (in STGD).
FT                                /FTId=VAR_012599.
FT   VARIANT    1886   1886       G -> E (in STGD; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008471.
FT   VARIANT    1890   1890       Missing (in STGD).
FT                                /FTId=VAR_008472.
FT   VARIANT    1896   1896       V -> D (in STGD).
FT                                /FTId=VAR_012600.
FT   VARIANT    1898   1898       R -> H (in STGD and ARMD2;
FT                                dbSNP:1800552).
FT                                /FTId=VAR_008473.
FT   VARIANT    1921   1921       V -> M.
FT                                /FTId=VAR_012601.
FT   VARIANT    1940   1940       L -> P (in STGD and FFM).
FT                                /FTId=VAR_012602.
FT   VARIANT    1948   1948       P -> L.
FT                                /FTId=VAR_008474.
FT   VARIANT    1961   1961       G -> E (in STGD and FFM; frequent
FT                                mutation; may be associated with ARMD2;
FT                                inhibition of ATP hydrolysis by retinal;
FT                                dbSNP:1800553).
FT                                /FTId=VAR_008475.
FT   VARIANT    1970   1970       L -> F (in ARMD2 and FFM; dbSNP:1800554).
FT                                /FTId=VAR_008476.
FT   VARIANT    1971   1971       L -> R (in FFM; highly reduced ATP-
FT                                binding capacity; abolishes basal and
FT                                retinal-stimulated ATP hydrolysis).
FT                                /FTId=VAR_012603.
FT   VARIANT    1975   1975       G -> R (in STGD).
FT                                /FTId=VAR_012604.
FT   VARIANT    1977   1977       G -> S (in STGD; highly reduced ATP-
FT                                binding capacity; inhibition of ATP
FT                                hydrolysis by retinal).
FT                                /FTId=VAR_008477.
FT   VARIANT    2027   2027       L -> F (in STGD and FFM; highly reduced
FT                                ATP-binding capacity).
FT                                /FTId=VAR_008478.
FT   VARIANT    2030   2030       R -> Q (in STGD and FFM).
FT                                /FTId=VAR_008480.
FT   VARIANT    2035   2035       L -> P (in STGD).
FT                                /FTId=VAR_012605.
FT   VARIANT    2038   2038       R -> W (in STGD; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008495.
FT   VARIANT    2050   2050       V -> L (in STGD).
FT                                /FTId=VAR_008481.
FT   VARIANT    2059   2059       G -> A.
FT                                /FTId=VAR_012606.
FT   VARIANT    2060   2060       L -> R (in CORD3).
FT                                /FTId=VAR_012607.
FT   VARIANT    2071   2071       Y -> F (in STGD).
FT                                /FTId=VAR_012608.
FT   VARIANT    2077   2077       R -> G (in STGD).
FT                                /FTId=VAR_012609.
FT   VARIANT    2077   2077       R -> W (in STGD; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008482.
FT   VARIANT    2096   2096       E -> K (in STGD; inhibition of ATP
FT                                hydrolysis by retinal).
FT                                /FTId=VAR_008483.
FT   VARIANT    2106   2106       R -> C (in STGD and FFM; reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008484.
FT   VARIANT    2107   2107       R -> C (in STGD).
FT                                /FTId=VAR_012610.
FT   VARIANT    2107   2107       R -> H (in STGD; may predispose to
FT                                develop retinal toxicity after treatment
FT                                with chloroquine and hydroxychloroquine).
FT                                /FTId=VAR_008485.
FT   VARIANT    2128   2128       H -> R (in STGD).
FT                                /FTId=VAR_008486.
FT   VARIANT    2131   2131       E -> K (in STGD).
FT                                /FTId=VAR_008487.
FT   VARIANT    2139   2139       R -> W (in STGD).
FT                                /FTId=VAR_008488.
FT   VARIANT    2146   2146       G -> D (in CORD3).
FT                                /FTId=VAR_012611.
FT   VARIANT    2149   2149       R -> L (in STGD).
FT                                /FTId=VAR_012612.
FT   VARIANT    2150   2150       C -> R (in STGD).
FT                                /FTId=VAR_012613.
FT   VARIANT    2150   2150       C -> Y (in STGD and CORD3).
FT                                /FTId=VAR_008489.
FT   VARIANT    2160   2160       K -> R (in STGD).
FT                                /FTId=VAR_008490.
FT   VARIANT    2177   2177       D -> N (may be associated with ARMD2;
FT                                increased retinal-stimulated ATP
FT                                hydrolysis; dbSNP:1800555).
FT                                /FTId=VAR_008491.
FT   VARIANT    2216   2216       A -> V.
FT                                /FTId=VAR_012614.
FT   VARIANT    2229   2229       L -> P (in STGD).
FT                                /FTId=VAR_012615.
FT   VARIANT    2241   2241       L -> V (in STGD).
FT                                /FTId=VAR_012616.
FT   VARIANT    2255   2255       S -> I.
FT                                /FTId=VAR_009157.
FT   VARIANT    2263   2263       R -> L (in STGD).
FT                                /FTId=VAR_012617.
FT   MUTAGEN     966    966       G->D: Abolishes basal and retinal-
FT                                stimulated ATP hydrolysis.
FT   MUTAGEN     969    969       K->M: Abolishes basal and retinal-
FT                                stimulated ATP hydrolysis.
FT   MUTAGEN    1975   1975       G->D: Inhibition of retinal-stimulated
FT                                ATP hydrolysis.
FT   MUTAGEN    1978   1978       K->M: Inhibition of retinal-stimulated
FT                                ATP hydrolysis.
FT   CONFLICT    722    722       G -> V (in Ref. 2).
FT   CONFLICT    849    849       V -> C (in Ref. 1).
FT   CONFLICT    882    882       G -> S (in Ref. 1 and 3).
FT   CONFLICT    941    941       C -> S (in Ref. 2).
FT   CONFLICT   1116   1116       S -> P (in Ref. 1).
FT   CONFLICT   1125   1126       LL -> HQ (in Ref. 1).
FT   CONFLICT   1395   1395       P -> L (in Ref. 1 and 3).
FT   CONFLICT   1465   1465       S -> C (in Ref. 4).
FT   CONFLICT   1518   1518       S -> T (in Ref. 4).
FT   CONFLICT   1733   1733       M -> V (in Ref. 2).
FT   CONFLICT   1817   1817       E -> D (in Ref. 1 and 3).
FT   CONFLICT   1989   1989       T -> N (in Ref. 2).
FT   CONFLICT   2119   2119       E -> K (in Ref. 1).
SQ   SEQUENCE   2273 AA;  255941 MW;  6E7012D3041CD043 CRC64;
     MGFVRQIQLL LWKNWTLRKR QKIRFVVELV WPLSLFLVLI WLRNANPLYS HHECHFPNKA
     MPSAGMLPWL QGIFCNVNNP CFQSPTPGES PGIVSNYNNS ILARVYRDFQ ELLMNAPESQ
     HLGRIWTELH ILSQFMDTLR THPERIAGRG IRIRDILKDE ETLTLFLIKN IGLSDSVVYL
     LINSQVRPEQ FAHGVPDLAL KDIACSEALL ERFIIFSQRR GAKTVRYALC SLSQGTLQWI
     EDTLYANVDF FKLFRVLPTL LDSRSQGINL RSWGGILSDM SPRIQEFIHR PSMQDLLWVT
     RPLMQNGGPE TFTKLMGILS DLLCGYPEGG GSRVLSFNWY EDNNYKAFLG IDSTRKDPIY
     SYDRRTTSFC NALIQSLESN PLTKIAWRAA KPLLMGKILY TPDSPAARRI LKNANSTFEE
     LEHVRKLVKA WEEVGPQIWY FFDNSTQMNM IRDTLGNPTV KDFLNRQLGE EGITAEAILN
     FLYKGPRESQ ADDMANFDWR DIFNITDRTL RLVNQYLECL VLDKFESYND ETQLTQRALS
     LLEENMFWAG VVFPDMYPWT SSLPPHVKYK IRMDIDVVEK TNKIKDRYWD SGPRADPVED
     FRYIWGGFAY LQDMVEQGIT RSQVQAEAPV GIYLQQMPYP CFVDDSFMII LNRCFPIFMV
     LAWIYSVSMT VKSIVLEKEL RLKETLKNQG VSNAVIWCTW FLDSFSIMSM SIFLLTIFIM
     HGRILHYSDP FILFLFLLAF STATIMLCFL LSTFFSKASL AAACSGVIYF TLYLPHILCF
     AWQDRMTAEL KKAVSLLSPV AFGFGTEYLV RFEEQGLGLQ WSNIGNSPTE GDEFSFLLSM
     QMMLLDAAVY GLLAWYLDQV FPGDYGTPLP WYFLLQESYW LGGEGCSTRE ERALEKTEPL
     TEETEDPEHP EGIHDSFFER EHPGWVPGVC VKNLVKIFEP CGRPAVDRLN ITFYENQITA
     FLGHNGAGKT TTLSILTGLL PPTSGTVLVG GRDIETSLDA VRQSLGMCPQ HNILFHHLTV
     AEHMLFYAQL KGKSQEEAQL EMEAMLEDTG LHHKRNEEAQ DLSGGMQRKL SVAIAFVGDA
     KVVILDEPTS GVDPYSRRSI WDLLLKYRSG RTIIMSTHHM DEADLLGDRI AIIAQGRLYC
     SGTPLFLKNC FGTGLYLTLV RKMKNIQSQR KGSEGTCSCS SKGFSTTCPA HVDDLTPEQV
     LDGDVNELMD VVLHHVPEAK LVECIGQELI FLLPNKNFKH RAYASLFREL EETLADLGLS
     SFGISDTPLE EIFLKVTEDS DSGPLFAGGA QQKRENVNPR HPCLGPREKA GQTPQDSNVC
     SPGAPAAHPE GQPPPEPECP GPQLNTGTQL VLQHVQALLV KRFQHTIRSH KDFLAQIVLP
     ATFVFLALML SIVIPPFGEY PALTLHPWIY GQQYTFFSMD EPGSEQFTVL ADVLLNKPGF
     GNRCLKEGWL PEYPCGNSTP WKTPSVSPNI TQLFQKQKWT QVNPSPSCRC STREKLTMLP
     ECPEGAGGLP PPQRTQRSTE ILQDLTDRNI SDFLVKTYPA LIRSSLKSKF WVNEQRYGGI
     SIGGKLPVVP ITGEALVGFL SDLGRIMNVS GGPITREASK EIPDFLKHLE TEDNIKVWFN
     NKGWHALVSF LNVAHNAILR ASLPKDRSPE EYGITVISQP LNLTKEQLSE ITVLTTSVDA
     VVAICVIFSM SFVPASFVLY LIQERVNKSK HLQFISGVSP TTYWVTNFLW DIMNYSVSAG
     LVVGIFIGFQ KKAYTSPENL PALVALLLLY GWAVIPMMYP ASFLFDVPST AYVALSCANL
     FIGINSSAIT FILELFENNR TLLRFNAVLR KLLIVFPHFC LGRGLIDLAL SQAVTDVYAR
     FGEEHSANPF HWDLIGKNLF AMVVEGVVYF LLTLLVQRHF FLSQWIAEPT KEPIVDEDDD
     VAEERQRIIT GGNKTDILRL HELTKIYPGT SSPAVDRLCV GVRPGECFGL LGVNGAGKTT
     TFKMLTGDTT VTSGDATVAG KSILTNISEV HQNMGYCPQF DAIDELLTGR EHLYLYARLR
     GVPAEEIEKV ANWSIKSLGL TVYADCLAGT YSGGNKRKLS TAIALIGCPP LVLLDEPTTG
     MDPQARRMLW NVIVSIIREG RAVVLTSHSM EECEALCTRL AIMVKGAFRC MGTIQHLKSK
     FGDGYIVTMK IKSPKDDLLP DLNPVEQFFQ GNFPGSVQRE RHYNMLQFQV SSSSLARIFQ
     LLLSHKDSLL IEEYSVTQTT LDQVFVNFAK QQTESHDLPL HPRAAGASRQ AQD
//
